Analysts Set Certara, Inc. (NASDAQ:CERT) PT at $17.79

Certara, Inc. (NASDAQ:CERT) has been given a consensus rating of “Hold” by the nine analysts that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $17.79.

Several research firms have commented on CERT. UBS Group lowered their price target on Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Barclays lowered their target price on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. KeyCorp lowered their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Robert W. Baird cut their target price on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th.

Certara Stock Performance

Shares of CERT opened at $10.70 on Friday. Certara has a 1 year low of $10.35 and a 1 year high of $19.87. The company’s 50 day simple moving average is $12.82 and its 200 day simple moving average is $15.16. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -27.44, a PEG ratio of 5.17 and a beta of 1.49. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. On average, sell-side analysts predict that Certara will post 0.27 EPS for the current year.

Insider Activity

In related news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 2.39% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CERT. Mubadala Investment Co PJSC acquired a new stake in shares of Certara in the fourth quarter valued at about $169,135,000. Franklin Resources Inc. raised its stake in shares of Certara by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 1,820,864 shares of the company’s stock valued at $32,029,000 after purchasing an additional 138,682 shares during the period. Sei Investments Co. raised its stake in shares of Certara by 12.4% during the first quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock valued at $12,793,000 after purchasing an additional 79,013 shares during the period. Edmond DE Rothschild Holding S.A. lifted its position in shares of Certara by 93.1% during the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock worth $13,532,000 after purchasing an additional 370,820 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Certara in the fourth quarter valued at $14,262,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.